Table 1 General demographics, visual outcomes and degree of inflammation
PatientGenderAge at initiation of therapyDiagnosisDrugBCVA initialBCVA finalDegree of inflammationDegree of inflammationTreatment duration (months)
1M6JIA-UAdalimumab20/2020/151+Quiet3
2F16JIA-UAdalimumab20/5020/403+Quiet8.2
3F10JIA-UAdalimumab20/2020/202.5+1.5+1.3
4F13ABDAdalimumab20/2020/201+Quiet26
5F4JIA-UAdalimumab20/2020/253+1+8.2
6F11JIA-UInfliximab20/2020/201+1+12
7M7JIA-UInfliximab20/2020/203+1+8.6
8F4JIA-UInfliximab20/6020/201.5+Quiet9.5
9F17JIA-UInfliximab20/2520/20QuietQuiet16.8
10F5JIA-UInfliximab20/2520/153+Quiet5.1
11F11JIA-UInfliximab20/2020/201+Quiet17.1
12F14JIA-UInfliximab20/3020/20QuietQuiet26.9
13F6JIA-UInfliximab20/2020/201+Quiet22
14F15JIA-UInfliximab20/3020/20Quiet1+50.8
15F6JIA-UInfliximab20/2020/203+Quiet5.1
16F18JIA-UInfliximab20/2020/154+Quiet9
17M6JIA-UInfliximab20/2020/204+1+30
18M11JIA-UInfliximab20/1520/152+1+5.7
19F8Keratouveitis*Daclizumab20/3020/204+Quiet54.1
20M12Sarcoidosis†Daclizumab20/2520/253+Quiet30.9
21F18Anterior uveitis*Daclizumab20/2520/253+Quiet14.5
22F12SarcoidosisDaclizumab20/2020/201+Quiet14.6
23F17Panuveitis*Daclizumab20/2020/203+1+10.5
  • BCVA, Best corrected visual acuity; JIA-U, juvenile idiopathic arthritis-associated uveitis; Adamantiades–Behçet’s disease. *Idiopathic; panuveitis.